





Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messinger Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Jeffrey T. Helvey Heidi L. Kraus Albert L. Ferro* Donald R. Banowit Peter A. Jackman Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono Virgil Lee Beaston Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Christine M. Lhuller Rae Lynn P. Guest George S. Bardmesser Daniel A. Klein* Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller* LuAnne M. DeSantis Ann E. Summerfield Aric W. Ledford* Helene C. Carlson Timothy A. Doyle* Gaby L. Longsworth Lori A. Gordon* Nicole D. Dretar*

Jyoti C. Jyer*
Laura A. Vogel

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Aaron L. Schwartz
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford
Michelle K. Holoubek
Robert H. DeSelms

Ted J. Ebersole

Julie A. Heider Mita Mukherjee Scott M. Woodhouse Michael G. Penn Christopher J. Walsh

Of Counsel Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

*Admitted only in Maryland *Admitted only in Virginia •Practice Limited to Federal Agencies

February 11, 2005

WRITER'S DIRECT NUMBER: (202) 772-8589 INTERNET ADDRESS: LARRYB@SKGF.COM

Art Unit 1646

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 09/475,158; Filed: December 30, 1999

For: PTH Functional Domain Conjugate Peptides, Derivatives Thereof and

Novel Tethered Ligand-Receptor Molecules

Inventors:

GARDELLA et al.

Our Ref:

0609.4780001/LBB

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. SKGF Cover Letter;
- 2. Amendment and Reply Under 37 C.F.R. § 1.116; and
- 3. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Laure B Bugarshy

Lawrence B. Bugaisky Attorney for Applicants

Registration No. 35,086

Sherrie, Kessler, Goldstein & Fox P.L.C. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.sags.com

FEB 1 1 2005 5 N T.

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

mornia plication of:

Confirmation No.:

6018

GARDELLA et al.

Art Unit:

1646

Appl. No.:

09/475,158

Examiner:

Ruixiang, Li

Filed:

December 30, 1999

Atty. Docket:

0609.4780001/LBB

For:

PTH Functional Domain Conjugate Peptides, Derivatives Thereof and Novel Tethered Ligand-Receptor

Molecules

Amendment and Reply Under 37 C.F.R. § 1.116

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the final Office Action dated **November 22, 2004**, Applicants submit the following Amendment and Reply. Applicants also wish to thank the Examiner for suggestions made during the telephone discussion of November 24, 2004. The amendment and reply place the claims in condition for allowance or better condition for appeal and raises no new issues. Therefore entry of the amendment is respectfully requested

This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, a complete listing of all of the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims;
- (C) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a),

and any fees required therefore (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.